These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 10117574)

  • 1. Centacor stock dips again after articles on Centoxin.
    Wagner M
    Mod Healthc; 1992 Apr; 22(17):20. PubMed ID: 10117574
    [No Abstract]   [Full Text] [Related]  

  • 2. FDA withholds approval of anti-infection drug; manufacturer's stock price plunges.
    Wagner M
    Mod Healthc; 1992 Apr; 22(16):6. PubMed ID: 10117563
    [No Abstract]   [Full Text] [Related]  

  • 3. Spinning the wheel on ImClone.
    Varchaver N
    Fortune; 2003 Apr; 147(8):123-5. PubMed ID: 12728651
    [No Abstract]   [Full Text] [Related]  

  • 4. AHP's awful losing streak.
    Whitford D
    Fortune; 1999 Nov; 140(10):52, 56. PubMed ID: 10662389
    [No Abstract]   [Full Text] [Related]  

  • 5. Sporicidin update: are the government's regulatory teeth tearing a hole in industry?
    Healthc Hazard Mater Manage; 1993 Apr; 6(7):10-1. PubMed ID: 10125098
    [No Abstract]   [Full Text] [Related]  

  • 6. Biotech bonanza.
    Stipp D
    Fortune; 1999 Nov; 140(9):333-4. PubMed ID: 10623111
    [No Abstract]   [Full Text] [Related]  

  • 7. The drug that could have been.
    Schultz S
    US News World Rep; 2002 Aug; 133(7):18, 20-3. PubMed ID: 12195678
    [No Abstract]   [Full Text] [Related]  

  • 8. As Genzyme flounders, competitors and activist investors swoop in.
    Allison M
    Nat Biotechnol; 2010 Jan; 28(1):3-4. PubMed ID: 20062016
    [No Abstract]   [Full Text] [Related]  

  • 9. A bitter pill for one Merck critic.
    McLean B
    Fortune; 2004 Dec; 150(12):58. PubMed ID: 15617422
    [No Abstract]   [Full Text] [Related]  

  • 10. Perspectives. CMS and Wall Street report...
    Med Health; 2003 Jan; 57(4):7-8. PubMed ID: 12602066
    [No Abstract]   [Full Text] [Related]  

  • 11. How the street sees biotech.
    Lashinsky A
    Fortune; 2003 Jun; 147(11):86. PubMed ID: 12800576
    [No Abstract]   [Full Text] [Related]  

  • 12. Adoption agent.
    Peota C
    Minn Med; 2005 Mar; 88(3):8-9. PubMed ID: 15852583
    [No Abstract]   [Full Text] [Related]  

  • 13. Sporicidin responds to the recall of its products.
    Healthc Hazard Mater Manage; 1992 Aug; 5(11):8-11. PubMed ID: 10121070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health purveyors that look hale.
    McFadden M
    Fortune; 1986 May; 113(11):147-8, 150. PubMed ID: 10276676
    [No Abstract]   [Full Text] [Related]  

  • 15. Healthcare stocks soar on wings of restructuring.
    Lutz S
    Mod Healthc; 1996 Jan; 26(2):3. PubMed ID: 10153952
    [No Abstract]   [Full Text] [Related]  

  • 16. Health-care stocks that will profit under reform.
    Schutzer AI
    Med Econ; 1994 Jan; 71(1):30-2, 34, 36. PubMed ID: 10130875
    [No Abstract]   [Full Text] [Related]  

  • 17. Eli Lilly enters venture capital arena.
    Fletcher L
    Nat Biotechnol; 2001 Nov; 19(11):997-8. PubMed ID: 11689830
    [No Abstract]   [Full Text] [Related]  

  • 18. Biotech's next big blowup?
    Stires D
    Fortune; 2002 Mar; 145(6):154. PubMed ID: 11913033
    [No Abstract]   [Full Text] [Related]  

  • 19. Antivirals--an increasingly healthy investment.
    McCarthy B
    Nat Biotechnol; 2007 Dec; 25(12):1390-3. PubMed ID: 18066033
    [No Abstract]   [Full Text] [Related]  

  • 20. Any diamonds in the diagnostic coal?
    Jacobs T
    Nat Biotechnol; 2006 Aug; 24(8):930. PubMed ID: 16900133
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.